Association of biomarkers with dysplasia in the per-biopsy analysis
| Biomarker | Missing values (%) | Biomarker outcome | HGD/EC | Any dysplasia | ||||
|---|---|---|---|---|---|---|---|---|
| No | Yes | p Value | No | Yes | p Value | |||
| HPP1 methylation | 19.1 | Negative | 59 (22.9%) | 3 (7.1%) | 0.02 | 56 (24.0%) | 6 (9.0%) | <0.01 |
| Positive | 199 (77.1%) | 39 (92.9%) | 177 (76.0%) | 61 (91.0%) | ||||
| RUNX3 methylation | 19.1 | Negative | 102 (39.5%) | 6 (14.3%) | <0.01 | 97 (41.6%) | 11 (16.4%) | <0.01 |
| Positive | 156 (60.5%) | 36 (85.7%) | 136 (58.4%) | 56 (83.6%) | ||||
| p16 methylation | 19.1 | Negative | 143 (55.4%) | 12 (28.6%) | <0.01 | 132 (56.7%) | 23 (34.3%) | <0.01 |
| Positive | 115 (44.6%) | 30 (71.4%) | 101 (43.3%) | 44 (65.7%) | ||||
| p53 IHC | 13.2 | Negative | 196 (70.5%) | 3 (6.8%) | <0.01 | 189 (76.8%) | 10 (13.2%) | <0.01 |
| Positive | 82 (29.5%) | 41 (93.2%) | 57 (23.2%) | 66 (86.8%) | ||||
| Cyclin A IHC | 14.0 | Negative | 238 (85.0%) | 8 (20.5%) | <0.01 | 223 (88.8%) | 23 (33.8%) | <0.01 |
| Positive | 42 (15.0%) | 31 (79.5%) | 28 (11.2%) | 45 (66.2%) | ||||
| Tetraploidy | 19.7 | Negative | 182 (69.2%) | 20 (57.1%) | 0.15 | 171 (72.2%) | 31 (50.8%) | <0.01 |
| Positive | 81 (30.8%) | 15 (42.9%) | 66 (27.8%) | 30 (48.2%) | ||||
| Aneuploidy | 19.7 | Negative | 232 (88.2%) | 10 (28.6%) | <0.01 | 216 (91.1%) | 26 (42.6%) | <0.01 |
| Positive | 31 (11.8%) | 25 (71.4%) | 21 (8.9%) | 35 (57.4%) | ||||
| 17p LOH | 27.4 | Negative | 112 (49.3%) | 7 (16.7%) | <0.01 | 107 (51.9%) | 12 (19.0%) | <0.01 |
| Positive | 115 (50.7%) | 35 (83.3%) | 99 (48.1%) | 51 (81.0%) | ||||
| 9p LOH | 28.5 | Negative | 43 (19.2%) | 5 (12.2%) | 0.29 | 40 (19.5%) | 8 (13.3%) | 0.27 |
| Positive | 181 (80.8%) | 36 (87.8%) | 165 (80.5%) | 52 (86.7%) | ||||
Each p value is obtained from a χ2 test on the 2×2 table to its left. Any dysplasia refers to combination of low-grade dysplasia (LGD), HGD and EC.
EC, early cancer; HGD, high-grade dysplasia; IHC, immunohistochemistry; LOH, loss of heterozygosity.